此語言的正文尚未翻譯，暫以英文顯示。
Insilico Medicine used a generative platform to propose TNIK as a target in idiopathic pulmonary fibrosis and to design rentosertib (formerly ISM001-055). Nature Medicine published a 12-week randomized phase 2a trial in 2025. The primary endpoint was safety, not lung function. The molecule is investigational. A small secondary signal is not an approved therapy.
A multicenter, double-blind, placebo-controlled trial in adults with idiopathic pulmonary fibrosis, run at sites in China (NCT05938920).
Seventy-one patients were randomized. Treatment-emergent adverse events were in a similar range across arms (about 71–83%). The most discussed discontinuation events involved liver-test abnormalities or diarrhea. At 60 mg once daily, mean forced vital capacity changed by +98.4 mL versus −20.3 mL on placebo. That lung-function comparison was secondary, the samples were small, and the authors said it needs a larger, longer trial.
Xu et al., Nature Medicine · 2025年6月3日 · 年份 2025
收入索引 2026年11月2日
打開來源供教育和市場掃描的目錄條目。不是醫療建議，也不是背書。
藥物發現與製藥
廠商報告Trial-matching tools read structured fields and sometimes the free-text note to list studies a patient might qualify for. Tempus, Flatiron, and Deep 6 AI are examples of companies that sell a version of this. A research coordinator still checks every criterion against the chart. A match list is not enrollment, and it is not a treatment recommendation.
Tempus · Flatiron · Deep 6 AI